143 related articles for article (PubMed ID: 32358546)
1. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant.
Al Saleh AS; Sidiqi MH; Lee J; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Skaer CA; Wittwer SK; Wolf RC; Hogan WJ; Kumar SK; Jacob E; Gertz MA
Bone Marrow Transplant; 2020 Nov; 55(11):2132-2137. PubMed ID: 32358546
[TBL] [Abstract][Full Text] [Related]
2. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant.
Watson AN; Shah SA; Shalhoub SD; Piedra KM; Komanduri KV; Kwon D; Pereira DL
J Oncol Pharm Pract; 2023 Sep; 29(6):1398-1403. PubMed ID: 36245321
[TBL] [Abstract][Full Text] [Related]
3. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
[No Abstract] [Full Text] [Related]
4. Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma.
Merino A; Shanley R; Rashid F; Langer J; Dolan M; Tu S; Jurdi NE; Rogosheske J; Hanna K; DeFor T; Janakiram M; Weisdorf D
Front Immunol; 2024; 15():1310752. PubMed ID: 38504993
[TBL] [Abstract][Full Text] [Related]
5. Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion.
Shuman K; Palmer S; Anders B; Moore D; Ptachcinski J; Grgic T; Alexander M; Hill L; Sung AD; Armistead PM; Kennedy L; Shaw JR
Transplant Cell Ther; 2023 Jan; 29(1):36.e1-36.e5. PubMed ID: 36404519
[TBL] [Abstract][Full Text] [Related]
6. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
[TBL] [Abstract][Full Text] [Related]
7. Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK; Harvey RD
Pharmacotherapy; 2022 Mar; 42(3):233-240. PubMed ID: 35122287
[TBL] [Abstract][Full Text] [Related]
8. Fractionated stem cell infusions for patients with plasma cell myeloma undergoing autologous hematopoietic cell transplantation.
Landau H; Wood K; Chung DJ; Koehne G; Lendvai N; Hassoun H; Lesokhin A; Hoover E; Zheng J; Devlin SM; Giralt S
Leuk Lymphoma; 2016 Aug; 57(8):1781-5. PubMed ID: 26758672
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
[TBL] [Abstract][Full Text] [Related]
10. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
Hong JY; Choi MK; Kim DH; Kim SJ; Kim K; Kim WS; Chung CW; Kim HO; Min YH; Jang JH
Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
[TBL] [Abstract][Full Text] [Related]
13. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
[TBL] [Abstract][Full Text] [Related]
14. Impact of chemotherapy on the mobilisation, harvest and economic costs of autologous peripheral stem cell transplantation in patients with multiple myeloma.
Jerjis S; Croockewit S; Preijers F; Schaap N; De Witte T
Leuk Lymphoma; 2000 May; 37(5-6):551-60. PubMed ID: 11042515
[TBL] [Abstract][Full Text] [Related]
15. Cryopreserved versus non-cryopreserved stem cell autografts in multiple myeloma a restrospective cohort study.
Pessoa JM; da Rosa EL; Américo AD; Motta CL; de Oliveira CZ; Concilio RR; Amigo Filho JU; Marret ACF; Lazar AE; De Gusmão BM; Scheinberg P; Kerbauy FR
Bone Marrow Transplant; 2022 Aug; 57(8):1313-1318. PubMed ID: 35637267
[TBL] [Abstract][Full Text] [Related]
16. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
[TBL] [Abstract][Full Text] [Related]
17. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
18. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
19. Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study.
Garderet L; Ouldjeriouat H; Bekadja MA; Daguenet E; Bigot N; Vincent L; Roos-Weil D; Vignon M; Ikhlef S; Abraham J; Escoffre-Barbe M; Lioure B; Nacer RA; Lafon I; Mariette C; Karlin L; Morel P; Gilis L; Le Ray E; Blouet A; Nguyen Quoc S; Boffa JJ; Ronco P; Lambert J; Cornillon J
Br J Haematol; 2024 Apr; 204(4):1450-1458. PubMed ID: 37953476
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
